BioVeda Capital

Sensely is a developer of avatar and chatbot-based platform designed to assist insurance plan members and patients. The company's platform leverages conversational interfaces and provides virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide, enabling enterprises to converse with their members in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology.

From a modest start in 2013, when they had just three Fortune 500 clients, CXA has grown to become Asia’s leading Insurtech start-up - affirmed by over 600 clients and backed by a group of astute investors who understand the value and transformative potential of CXA’s groundbreaking platform. Employees are now able to proactively manage their health by choosing the best-suited insurance, wellness and disease management offerings while employers are able to view aggregated health and claims analytics of their workforce to prioritise interventions that reduce costs and improve workplace health, productivity and employee engagement.

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

Biolidics is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Inspired Capital plc aim is to make borrowing natural and affordable for every small business. They are making it easier, faster and smoother for small businesses to get the funds they need. They want to make sure every small business gets the right product with the minimum of fuss and delay that will allow them to run their business as they want. Whether they want to open a new branch, employ another member of staff, invest in new equipment or just keep their cash flow ticking over, their lending products are here to help. Over the long term.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

NewBiotics transforms drug resistances into therapeutic advantages. It focuses on the discovery and development of drug molecules that leverage the cycle of drug resistance in both cancer and infectious diseases. NewBiotics is a U.S.-based company that was founded in 1997 and the company was acquired by Celmed Biosciences on June 7, 2004.